Probi AB
STO:PROB

Watchlist Manager
Probi AB Logo
Probi AB
STO:PROB
Watchlist
Price: 251 SEK -5.28% Market Closed
Market Cap: 2.9B SEK
Have any thoughts about
Probi AB?
Write Note

Relative Value

The Relative Value of one PROB stock under the Base Case scenario is 213.32 SEK. Compared to the current market price of 251 SEK, Probi AB is Overvalued by 15%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PROB Relative Value
Base Case
213.32 SEK
Overvaluation 15%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
44
vs Industry
63
Median 3Y
4.1
Median 5Y
4.8
Industry
8.1
Forward
4.4
vs History
4
vs Industry
1
Median 3Y
53.5
Median 5Y
50.4
Industry
23
Forward
67.9
vs History
14
vs Industry
6
Median 3Y
26.1
Median 5Y
26.9
Industry
23.4
vs History
9
vs Industry
2
Median 3Y
44.7
Median 5Y
46.9
Industry
27.3
vs History
49
vs Industry
41
Median 3Y
1.8
Median 5Y
2.2
Industry
2.6
vs History
46
vs Industry
55
Median 3Y
3.6
Median 5Y
4.4
Industry
8.1
Forward
4
vs History
30
vs Industry
31
Median 3Y
9.2
Median 5Y
10.6
Industry
9.6
vs History
11
vs Industry
3
Median 3Y
18.9
Median 5Y
19
Industry
4.3
Forward
22.2
vs History
4
vs Industry
0
Median 3Y
39
Median 5Y
35.4
Industry
3.8
Forward
190.5
vs History
17
vs Industry
5
Median 3Y
22.8
Median 5Y
23.7
Industry
6
vs History
9
vs Industry
3
Median 3Y
36.2
Median 5Y
36.2
Industry
3.8
vs History
47
vs Industry
45
Median 3Y
1.9
Median 5Y
2.3
Industry
4.8

Multiples Across Competitors

PROB Competitors Multiples
Probi AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Probi AB
STO:PROB
2.9B SEK 4.4 208.7 25.3 645
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 563 478.2 -178 533.6 -216 796.7 -214 322.8
US
Abbvie Inc
NYSE:ABBV
300.2B USD 5.4 59 14.8 22.8
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 4.9 37.4 17.5 33.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.6B USD 11.9 -263.9 26.7 28
US
Gilead Sciences Inc
NASDAQ:GILD
114.6B USD 4.1 910.1 10.1 10.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 875.5 -478.6 -521.2 -507.3
AU
CSL Ltd
ASX:CSL
137.3B AUD 6 33.7 20.8 25.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
87.6B USD 6.3 18.8 17.3 19.2
US
Seagen Inc
F:SGT
39.3B EUR 18.1 -55.4 -59.5 -53.7
NL
argenx SE
XBRU:ARGX
34.1B EUR 18.5 -129.9 -104.5 -76.1
P/E Multiple
Earnings Growth
SE
Probi AB
STO:PROB
Average P/E: 211.3
208.7
190%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -263.9
42%
US
Gilead Sciences Inc
NASDAQ:GILD
910.1
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.7
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
SE
Probi AB
STO:PROB
Average EV/EBITDA: 18.9
25.3
51%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.8
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
SE
Probi AB
STO:PROB
Average EV/EBIT: 112
645
369%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.2
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
25.9
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.2
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

See Also

Discover More
Back to Top